Tirzepatide Trial Investigates Efficacy for Binge-Eating Disorder and Obesity

Approximately 3% of adults experience Binge-Eating Disorder (BED), a serious condition characterized by recurrent episodes of consuming unusually large amounts of food, often accompanied by feelings of loss of control. BED frequently co-occurs with obesity, exacerbating health risks and impacting quality of life. Current treatments, such as lisdexamfetamine dimesylate, can be effective but may have limitations or side effects, highlighting a critical need for novel therapeutic options. This study aims to evaluate if tirzepatide, a dual GLP-1/GIP receptor agonist, offers superior efficacy and safety for adults with both obesity and BED.

As this is a recruiting clinical trial, specific results are not yet available. However, the study is rigorously designed to evaluate several key efficacy and safety endpoints. The primary objective is to determine if tirzepatide can achieve a statistically significant reduction in the frequency of binge-eating days compared to both placebo and lisdexamfetamine dimesylate over the study duration. The trial aims to demonstrate that tirzepatide leads to a superior reduction in weekly binge-eating episodes, potentially targeting a >50% decrease from baseline, alongside a significant improvement in overall body weight, with an anticipated 15-20% total body weight loss. Secondary endpoints include assessing improvements in BED severity scores, quality of life metrics, and comparing the safety and tolerability profiles of tirzepatide against the active comparator and placebo, expecting a favorable safety profile consistent with its known mechanisms.